BriaCell Therapeutics’ (BCTX) Buy Rating Reiterated at HC Wainwright

BriaCell Therapeutics (NASDAQ:BCTX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $15.00 price target on the stock.

BriaCell Therapeutics Price Performance

BCTX opened at $0.66 on Thursday. The stock’s 50 day simple moving average is $0.84 and its 200 day simple moving average is $0.89. BriaCell Therapeutics has a 1 year low of $0.46 and a 1 year high of $5.97. The firm has a market cap of $23.88 million, a price-to-earnings ratio of -0.56 and a beta of 1.46.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its quarterly earnings results on Monday, October 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.45. As a group, sell-side analysts anticipate that BriaCell Therapeutics will post -1.01 EPS for the current year.

Institutional Investors Weigh In On BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. acquired a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.